Transgender women had higher rates of venous thrombotic events with cross-sex hormones.
The current study sought to compare the incidence of acute cardiovascular events among transgender persons.
Current oral contraceptive products contain lower doses of estrogen than those used in the past, prompting reconsideration of risks and benefits.
Transgender and gender nonconforming youth should be counseled regarding fertility preservation before undergoing hormone therapy.
Researchers sought to identify associations of female reproductive factors with incidence of total knee arthroplasty in osteoarthritis.
Researchers examined the effect of menopausal hormone therapy on left ventricular and left atrial chamber structure and function changes, which are markers of subclinical cardiovascular disease.
Physicians should be aware that the benefit of menopausal hormone therapy (MHT) on body composition might rapidly disappear after its withdrawal and strongly encourage women to optimize nutrition and increase physical activity when stopping MHT.
Researchers assessed the effects of 2 frequently used formulations of menopausal hormone therapy on brain structure and cognition 3 years after the completion of a randomized clinical trial.
A new study presented at ENDO 2018 finds that giving 1 year of estrogen replacement to female athletes with exercise-induced menstrual irregularities improves drive for thinness, body dissatisfaction, and uncontrolled eating.
In a limited systematic review, hormonal therapy with gonadotropin-releasing hormone analogs produced some suppression of secondary sexual function, with more success in promoting anticipated masculinization or feminization with the use of testosterone or estrogen, respectively.
Researchers examined the correlation between Cobb angle of kyphosis from lateral spine radiographs and pattern of self-reported menopausal hormone therapy use.
Thyroid hormone supplementation may be a promising treatment for idiopathic pulmonary fibrosis [PreClinical]January 21, 2018
An enzyme involved in thyroid hormone activation was found to be elevated in patients with pulmonary fibrosis.
The use of hormone therapy up to 5 years after onset of menopause is associated with a lower risk for ischemic and hemorrhagic stroke compared with late hormone therapy initiation or no hormone therapy use.
A recent literature review and meta-analysis indicates that growth hormone therapy may reduce the risk for fracture in patients with osteoporosis.
To update its 2012 recommendation, the US Preventive Services Task Force reviewed evidence on the benefits and harms of systemic hormone therapy for the prevention of chronic conditions in postmenopausal women.
There may be other roles of estradiol therapy besides relief from menopause-related symptoms, including limiting effects of stress on working memory.
Rates of cBHT prescriptions are not yet being systemically tracked, and few data exist to demonstrate the safety, efficacy, or utility of the treatment.
Lifestyle modification and an individualized treatment approach are effective strategies for managing menopausal symptoms in breast cancer survivors who are largely advised to avoid hormone replacement therapy.
The newly released guidelines include updated language to reflect DSM-V changes, greater flexibility in treatment, and recommendations for CVD, bone health, and prostate cancer screening.
The effect of 1 year of cross-sex hormone therapy on bone mineral density was examined in transgender men and women.
Primary prevention of cardiovascular disease through risk factor modification, including tobacco cessation, maintenance of a body mass index, and management of abnormal lipid levels, diabetes, and hypertension, is of great importance for the health of transgender individuals.
HRT in postmenopausal women was linked to lower CAC scores and a lower risk of long-term, all-cause mortality.
In postmenopausal women taking hormone therapy, risk for death from vascular dementia appeared to be reduced.
Starting testosterone treatment is associated with an increased risk of venous thromboembolism (VTE), peaking within 6 months and declining thereafter.
Men treated with implantable testosterone pellets have a statistically significant increase in mean hematocrit, but it is unlikely to be clinically relevant.
The use of menopausal hormone therapy was associated with improved bone mineral density and better bone microarchitecture.
Use of estrogen-containing contraceptives were linked to significantly higher vitamin D levels.
Hormone Replacement Therapy vs Combination Oral Contraceptive for Bone Health in Premature Ovarian FailureJuly 08, 2016
In women with premature ovarian failure, hormone replacement therapy was associated with greater increases in bone mineral density.
In light of ELITE trial results, estradiol hormone therapy may have a role in coronary heart disease treatment.
Men using testosterone gel experienced improvements in sex drive, sexual activity, and erectile function.
Endocrinology Advisor Articles
- Relationship Between HbA1c and Coronary Artery Disease
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Nonfunctioning Adrenal Incidentaloma Associated With Metabolic Syndrome
- Weight Gain After Quitting Smoking May Increase Risk for T2D
- In Teens, Young Adults, High BMI May Hurt Cardiovascular Health
- Obesity Paradox Affects Type 2 Diabetes Mortality Rates
- Bi-Directional Association Observed Between Obstructive Sleep Apnea and Diabetes
- Real-World Data Show Reduced Fracture Rates in Teriparatide-Treated Osteoporosis